Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPFOP saracatinib trial in fibrodysplasia ossificans progressiva
2024-515186-33-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in fibrodysplasia ossificans progressiva (FOP) comparing Saracatinib randomized treatment arm with Placebo randomized treatment arm (2 arms). Primary endpoints: Primary safety, Primary efficacy - new active heterotopic ossification lesions by PET and 1 more. Planned start Jan 2020; status: authorised.
02
Drugs
saracatinib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2024-515186-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515186-33-00.